Faculty, Staff and Student Publications

Publication Date

9-13-2023

Journal

Cell Host & Microbe

DOI

10.1016/j.chom.2023.08.004

PMID

37657443

Abstract

Manipulation of the gut microbiome using live biotherapeutic products shows promise for clinical applications but remains challenging to achieve. Here, we induced dysbiosis in 56 healthy volunteers using antibiotics to test a synbiotic comprising the infant gut microbe, Bifidobacterium longum subspecies infantis (B. infantis), and human milk oligosaccharides (HMOs). B. infantis engrafted in 76% of subjects in an HMO-dependent manner, reaching a relative abundance of up to 81%. Changes in microbiome composition and gut metabolites reflect altered recovery of engrafted subjects compared with controls. Engraftment associates with increases in lactate-consuming Veillonella, faster acetate recovery, and changes in indolelactate and p-cresol sulfate, metabolites that impact host inflammatory status. Furthermore, Veillonella co-cultured in vitro and in vivo with B. infantis and HMO converts lactate produced by B. infantis to propionate, an important mediator of host physiology. These results suggest that the synbiotic reproducibly and predictably modulates recovery of a dysbiotic microbiome.

Keywords

Infant, Humans, Adult, Gastrointestinal Microbiome, Dysbiosis, Milk, Human, Synbiotics, Microbiota, Lactic Acid, Veillonella, B. infantis, Bifidobacterium, HMO, LBP, Veillonella, gut engraftment, gut microbiome, gut microbiota, human milk oligosaccharides, live biotherapeutic product, microbiome modulation, propionate

Published Open-Access

yes

fx1.jpg (54 kB)
Graphical Abstract

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.